Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25729638
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Curr+Transplant+Rep
2015 ; 2
(1
): 90-97
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Bioreactor Development for Lung Tissue Engineering
#MMPMID25729638
Panoskaltsis-Mortari A
Curr Transplant Rep
2015[Mar]; 2
(1
): 90-97
PMID25729638
show ga
RATIONALE: Much recent interest in lung bioengineering by pulmonary
investigators, industry and the organ transplant field has seen a rapid growth of
bioreactor development ranging from the microfluidic scale to the human-sized
whole lung systems. A comprehension of the findings from these models is needed
to provide the basis for further bioreactor development. OBJECTIVE: The goal was
to comprehensively review the current state of bioreactor development for the
lung. METHODS: A search using PubMed was done for published, peer-reviewed papers
using the keywords "lung" AND "bioreactor" or "bioengineering" or "tissue
engineering" or "ex vivo perfusion". MAIN RESULTS: Many new bioreactors ranging
from the microfluidic scale to the human-sized whole lung systems have been
developed by both academic and commercial entities. Microfluidic, lung-mimic and
lung slice cultures have the advantages of cost-efficiency and high throughput
analyses ideal for pharmaceutical and toxicity studies. Perfused/ventilated
rodent whole lung systems can be adapted for mid-throughput studies of lung
stem/progenitor cell development, cell behavior, understanding and treating lung
injury and for preliminary work that can be translated to human lung
bioengineering. Human-sized ex vivo whole lung bioreactors incorporating
perfusion and ventilation are amenable to automation and have been used for whole
lung decellularization and recellularization. Clinical scale ex vivo lung
perfusion systems have been developed for lung preservation and reconditioning
and are currently being evaluated in clinical trials. CONCLUSIONS: Significant
advances in bioreactors for lung engineering have been made at both the
microfluidic and the macro scale. The most advanced are closed systems that
incorporate pressure-controlled perfusion and ventilation and are amenable to
automation. Ex vivo lung perfusion systems have advanced to clinical trials for
lung preservation and reconditioning. The biggest challenges that lie ahead for
lung bioengineering can only be overcome by future advances in technology that
solve the problems of cell production and tissue incorporation.
free
free
free
